论文部分内容阅读
目的观察低分子肝素联合依达拉奉治疗进展型脑梗死的疗效。方法治疗组采用低分子肝素4100U皮下注射,每12小时1次,连用10d,依达拉奉30mg+生理盐水250ml静脉滴注,每日2次,连用14d;对照组仅用同剂量、疗程的低分子肝素。两组患者治疗前及治疗结束时均进行临床神经功能缺损程度评分及临床疗效评定。结果治疗组的治愈率、显效率及治疗后神经功能缺损程度评分与对照组比较,差异均有统计学意义(P均<0.01)。结论低分子肝素联合依达拉奉对进展型脑梗死有较好的疗效。
Objective To observe the curative effect of low molecular weight heparin combined with edaravone in treatment of advanced cerebral infarction. Methods The treatment group received low molecular weight heparin 4100U subcutaneously once every 12 hours for 10 days, edaravone 30mg plus normal saline 250ml intravenously twice daily for 14 days. The control group was given the same dose and the course of treatment was low Molecular heparin. Two groups of patients before treatment and at the end of treatment were clinical neurological deficit score and clinical efficacy evaluation. Results The cure rate, markedly effective rate and post-treatment neurological deficit score in the treatment group were significantly different from those in the control group (all P <0.01). Conclusion Low molecular weight heparin combined with edaravone has a good curative effect on advanced cerebral infarction.